Two-year efficacy and safety of botulinum a toxin intravesical injections in patients affected by refractory painful bladder syndrome

Current Drug Delivery

Volumn 7, Issue 1, 2010, Pages 1-4

  Giannantoni, Antonella ^a   Mearini, Ettore ^a   Del Zingaro, Michele ^a   Proietti, Silvia ^a   Porena, Massimo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Botulinum A toxin; Pain; Painful bladder syndrome

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; PENTOSAN POLYSULFATE; RESINIFERATOXIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLADDER DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; CYSTOSCOPY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MICTURITION; PAIN ASSESSMENT; PAINFUL BLADDER SYNDROME; PATIENT SATISFACTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY FREQUENCY; URODYNAMICS; VISUAL ANALOG SCALE;

ADULT; BOTULINUM TOXIN TYPE A; FEMALE; HUMANS; MIDDLE AGED; PAIN; PROSPECTIVE STUDIES; URINARY BLADDER DISEASES; URINATION;

EID: 77949670953     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720110790396463     Document Type: Article

References (28)

1. Diokno, A. C.; Homma, Y.; Sekiguchi, Y.; Suzuki, Y. Interstitial cystitis, gynaecologic pelvic pain, prostatitis, and their epidemiology. Int. J. Urol., 2003, (Suppl.) S3-S6.
2. Chancellor, M. B.; Yoshimura, N. Treatment of interstitial cystitis. Urology, 2004, 6, 85-92.
3. Apostolidis, A.; Dasgupta, P.; Denys, P.; Elneil, S.; Fowler, C. J.; Giannantoni, A.; Karsenty, G.; Schulte-Baukloh, H.; Schurch, B.; Wyndaele, J. J. Recommendations on the Use of Botulinum Toxin in the Treatment of Lower Urinary Tract Disorders and Pelvic Floor Dysfunctions; A European Consensus Report 2008/7. Eur. Urol., 2008.
4. Ward, A. B.; Molenaers, G.; Colosimo, C.; Berardelli, A. Clinical value of botulinum toxin in neurological indications. Eur. J. Neurol., 2006, 13, 20-26.
5. Vissel, J.; Muller, J.; Dressnandt, F.; Heinen, F.; Naumann, M.; Topka, H. Management of spasticity associated pain with botulinum A toxin. J. Pain Symptom Manag., 2000, 20, 44-49.
6. Porta, M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain, 2000, 85, 101-105.
7. Brisinda, G.; Bentivoglio, A. R.; Maria, G.; Albanese, A. Treatment with botulinum neurotoxin of gastrointestinal smooth muscles and sphincters spasms. Mov. Disord., 2004, 19, 146-156.
8. Gobel, H.; Heinze, A.; Heinze-Khun, K.; Austermann, K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain, 2001, 91, 195-199.
9. Troost, B. T. Botulinum toxin type A (Botox) in the treatment of migraine and other headaches. Expert Rev. Neurother., 2004, 4, 27-31.
10. Dodick, D. W.; Mauskop, A.; Elkind, A. H.; DeGryse, R.; Brin, M. F.; Silberstein, S. D. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache, 2005, 45, 315-324.
11. Jabbari, B.; Maher, N.; Difazio, M. P. Botulinum toxin A improved burining pain and allodynia in two patients with spinal cord pathology. Pain Med., 2003, 4, 206-210.
12. Cayan, S.; Coskun, B.; Bozlu, M.; Acar, D.; Akbay, E.; Ulusoy, E. Botulinum toxin type A may improves bladder function in a rat chemical cystitis model. Urol. Res., 2003, 30, 399-404.
13. Zermann, D. H.; Ishigooka, M.; Schubert, J. Trigonum and bladder base injection of severe urgency-frequency syndrome refractory to conservative medical treatment and electrical stimulation. Neurourol. Urodyn., 2001, 20, 412.
14. Duggan, M. J.; Quinn, C. P.; Chaddock, J. A.; Purkiss, J. R.; Alexander, F. C. G.; Doward, S.; Fooks, S. J.; Friis, L. M.; Hall, Y. H.; Kirby, E. R.; Leeds, N.; Moulsdale, H. J.; Dickenson, A.; Green, G. M.; Rahman, W.; Suzuki, R.; Shone, C. C.; Foster, K. A. Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a clostridium botulinum toxin A endopeptidase fragment and erythrina cristagalli lectin. J. Biol. Chem., 2002, 277, 34846-34852.
15. Apostolidis, A.; Dasgupta, P.; Fowler, C. J. Proposed mechanisms for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur. Urol., 2006, 49, 644-650.
16. Giannantoni, A.; Costantini, E.; Di Stasi, S. M.; Tascini, M. C.; Bini, V.; Porena, M. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur. Urol., 2006, 49, 704-709.
17. Giannantoni, A.; Porena, M.; Costantini, E.; Zucchi, A.; Mearini, L.; Mearini, E. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. J. Urol., 2008, 179, 1031-1034.
18. Abrams, P.; Cardozo, L.; Fall, M.; Griffiths, D.; Rosier. P.; Ulmsten, U.; van Kerrebroeck, P.; Victor, A.; Wein, A. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn, 2002, 21, 167-178.
19. Smith, C. P.; Radziszewski, P.; Borkowski, A.; Somogyi, G. T.; Boone, T. B.; Chancellor, M. B. Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology, 2004, 64, 871-875.
20. Abbruzzese, G.; Berardelli, A. Neurophysiological effects of botulinum toxin type A. Neurotox Res, 2006, 9, 109-114.
21. Trompetto C, Currà A, Buccolieri A, Suppa A, Abbruzzese G, Berardelli A. Botulinum toxin changes intrafusal feedback in dystonia: a study with the tonic vibration reflex. Mov. Disord., 2006, 21, 777-782.
22. Currà, A.; Berardelli, A. Do the unintended actions of BT at distant sites have clinical implications? Neurology, 2009, 72, 1095-1099.
23. Szallasi, A. Vanilloid (capsaicin) receptors in health and disease. A. J. Clin. Pathol., 2002, 118, 110-121.
24. Maggi, C. A. The Dual Sensory and Efferent Functions of the Capsaicin-Sensitive Primary Sensory Nerves in the Bladder and Urethra. In: The autonomic Nervous System: Nervous Control of the Urogenital System; Maggi, C.A., Ed.; Harwood Academic Publisher: London, 1953, 3, 389.
25. Liu, H. T.; Kuo, H. C. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology, 2007, 70, 463-468.
26. Welch, M. J.; Purkiss, J. R.; Foster, K. A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon., 2000, 38, 245-258.
27. Haferkamp, A.; Schurch, B.; Reitz, A.; Krengel, U.; Grosse, J.; Kramer, G.; Schumacher, S.; Bastian, P. J.; Büttner, R.; Müller, S. C.; Stöhrer, M. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder. Eur. Urol., 2004, 46, 784-791.
28. Apostolidis, A.; Jacques, T. S.; Freeman, A.; Kalsi, V.; Popat, R.; Gonzales, G.; Datta, S. N.; Ghazi-Noori, S.; Elneil, S.; Dasgupta, P.; Fowler, C. J. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur. Urol., 2008, 53, 1245-1253.